Skip to content

Clinical study on the treatment effects of modified Danzhi Xiaoyao Powder combined with art therapy on non-alcoholic fatty liver disease (NAFLD)

Clinical study on the treatment effects of modified Danzhi Xiaoyao Powder combined with art therapy on non-alcoholic fatty liver disease (NAFLD)

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082393
Enrollment
Unknown
Registered
2024-03-28
Start date
2024-03-29
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Intervention group:Combined intervention - art therapy
Intervention group:Combined intervention - Danzhi Xiaoyao Powder treatment
Control group :Only receiving Danzhi Xiaoyao Powder treatment

Sponsors

Yunnan Provincial Psychiatric Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1) Young male and female patients aged between 25 and 30 years, with the purpose to ensure that there are no liver function issues caused by the decline of other bodily functions. (2) Diagnosed with non-alcoholic fatty liver disease (NAFLD) via ultrasound or CT scan. (3) Have not received any other specific treatments for fatty liver disease. (4) On the basis of satisfying conditions 1, 2, and 3, only those who also have a low quality of life score on a mental health scale and exhibit high anxiety (on the HAMA (Hamilton Anxiety Rating Scale) can be included in the sample group

Exclusion criteria

Exclusion criteria: (1) Patients with severe cardiac, hepatic, renal, or other systemic diseases. (2) Pregnant or breastfeeding women. (3) Patients allergic to the study medication or materials. (4) Those who meet the diagnostic criteria for non-alcoholic fatty liver disease but do not have a low score in quality of life or do not meet the anxiety diagnostic criteria on the HAMA scale.

Design outcomes

Primary

MeasureTime frame
Aspartate aminotransferase;serum alanine aminotransferase;Glutamyl aminotransferase;Total cholesterol;LDL cholesterol;HDL cholesterol;Triglycerides;

Secondary

MeasureTime frame
Mental Health Scale Score;

Countries

China

Contacts

Public ContactLin Shaochen

Yunnan Provincial Psychiatric Hospital

3201809377@qq.com+86 178 6521 6918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026